Systemic Lupus Erythematosus

clinical topic updates

by Joan T. Merrill, MD

The currently available tools to identify patients who are at risk for complications of systemic lupus erythematosus (SLE), such as lupus nephritis......READ MORE

patient care perspectives

by Bevra H. Hahn, MD

B-cell–activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS), and a proliferation-inducing ligand (APRIL) are targets of therapeut......READ MORE

patient care perspectives

by Joan T. Merrill, MD

Developments in systemic lupus erythematosus (SLE) treatment and maintenance therapy include recent data with belimumab in patients with active lup......READ MORE

expert roundtables

by Bevra H. Hahn, MD; Joan T. Merrill, MD; and George C. Tsokos, MD

Treat-to-target strategies in systemic lupus erythematosus (SLE) involve setting the treatment target to complete remission or to low disease activ......READ MORE

expert roundtables

by Bevra H. Hahn, MD; Joan T. Merrill, MD; and George C. Tsokos, MD

Treatment goals in systemic lupus erythematosus (SLE) include achieving long-term patient survival, preventing flares and organ damage, and safegua......READ MORE